November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

New Combination Therapy Shows Promise for Rare Leukemia in Multicenter Study

❤️ Conditions & Care 2 min read 👁 5

A multicenter retrospective study published in Nature Health Sciences evaluated the VDVD drug regimen as an induction therapy for acute leukaemia of ambiguous lineage (ALAL), reporting high overall response rates.

❤️Conditions & Care

Key points

  • Evaluated a novel four-drug regimen (VDVD) for rare acute leukaemia of ambiguous lineage (ALAL)
  • Involved 19 patients across eight medical centers with a median age of 58
  • Observed a high overall response rate of nearly 95% after one induction cycle

A recent multicenter retrospective study published in Nature Health Sciences investigated the use of a novel drug regimen—known as VDVD—for patients diagnosed with de novo acute leukaemia of ambiguous lineage (ALAL), a rare and complex form of blood cancer. Researchers across eight hospitals in China evaluated 19 patients, with a median age of 58, who received the treatment comprising venetoclax, multi-frequency decitabine, vincristine, and dexamethasone. Dasatinib was additionally administered to patients who tested positive for the BCR::ABL1 genetic marker.

According to the findings, the overall response rate reached nearly 95 percent after a single induction cycle, with an 84 percent complete remission rate. The study noted no induction-related deaths, and secondary endpoints tracked overall survival, event-free survival, and disease-free survival over a median follow-up of 11 months.

Because ALAL typically carries unsatisfactory outcomes under conventional chemotherapy, these early findings suggest that the VDVD regimen may offer a manageable safety profile and notable efficacy. However, the study was a small, retrospective investigation, meaning larger clinical trials are necessary to confirm these results and determine long-term outcomes.

What to know: The VDVD therapy combines multiple agents to target rare leukemia, but findings are preliminary. Always consult a qualified healthcare provider for personalized medical decisions and treatment planning.

Source Nature Health Sciences — nature.com/articles/s41598-026-79095-9 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.